Sponsors (6)
This is not an official government website.
Copyright © 2026 PLEJ LC. All rights reserved.
Introduced July 23, 2025 by Kelly Morrison · Last progress July 23, 2025
Updates and reauthorizes federal newborn screening law by strengthening education for families and providers, expanding the advisory committee's public-facing materials and genetic testing guidance, improving national surveillance and data linkages, making certain research and pilot duties mandatory, and changing authorized funding language. It also clarifies that research using nonidentified newborn dried blood spots counts as "secondary research" under existing federal human-subjects rules. The bill directs federal agencies (including CDC and HHS advisory bodies) to standardize data collection and reporting across the newborn screening pathway, publish consumer-friendly nomination and technical assistance information, provide targeted education and re-engagement for families, require pilot demonstration of reliable screening technologies, and revise authorized funding figures (some numeric text appears incomplete or corrupted in the provided draft).
The bill strengthens newborn screening effectiveness, follow-up, and research—improving early diagnosis and program coordination—while raising privacy, cost, and implementation risks (and some funding ambiguities) that could strain state programs and public trust.
Newborns and their families: more infants will get timely follow-up, diagnosis, and tracked long-term care from initial screen through treatment, improving health outcomes.
State and local public-health programs and hospitals: will adopt standardized electronic data collection and reporting and better coordinate with federal clearinghouse activities, speeding follow-up and reducing missed cases.
Parents and families: will receive clearer, literacy-appropriate education and easier, consumer-friendly guidance for participating in the condition-nomination process and follow-up, improving understanding and engagement.
Infants and families: expanded electronic data-sharing and use of residual blood spots increases privacy and reidentification risks and may reduce notice/consent protections.
State governments, hospitals, and federal grantees: new requirements, IT upgrades, reporting, and consultative duties create additional administrative and implementation costs that may strain budgets and staff.
State programs and taxpayers: removing or weakening the 'supplement, not supplant' language and altered numeric authorizations (plus corrupted/incomplete text) could create ambiguity and risk displacement or reduction of existing state-funded screening efforts and grant funding.